Acer Expands Aspire AI Series with Six New Copilot+ PCs Powered by Next-Gen Processors
Most patients on mirikizumab-mrkz for Crohn’s disease achieved sustained clinical
18 February 2025 The latest results of VIVID-2 open-label extension study, had come out showing that the majority of patients with moderately to severely active Crohn’s disease receiving two years of continuous treatment with mirikizumab-mrkz, product Read More